A revolutionary drug that melts away cancer in some stage four patients has been given fast-track approval in the United States.
Melbourne-developed Venetoclax is one of a new generation of targeted drugs which attack specific cancer-causing biological factors like cell-structure mutations.
Robert Oblak was fighting a recurrence of chronic lymphocytic leukaemia, a cancer of the blood and bone marrow, when he was chosen to take part in a trial in 2013.
“I think I was the eleventh person in the world to have it,” he told 7.30. “It was amazing.” Within a year his leukaemia went into remission. “It causes no side-effects. Nothing, absolutely nothing,” he said.